Virgolini I - Search Results

1

Joint EANM/SNMMI procedure guideline for the use of ¹⁷⁷Lu-labeled PSMA-targeted radioligand-therapy (¹⁷⁷Lu-PSMA-RLT).

Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. Kratochwil C, et al. Among authors: virgolini i. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830-2845. doi: 10.1007/s00259-023-06255-8. Epub 2023 May 29. Eur J Nucl Med Mol Imaging. 2023. PMID: 37246997 Free PMC article.

2

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A. Virgolini I, et al. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):2004-10. doi: 10.1007/s00259-010-1512-3. Eur J Nucl Med Mol Imaging. 2010. PMID: 20596866

3

[68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.

Knetsch PA, Petrik M, Griessinger CM, Rangger C, Fani M, Kesenheimer C, von Guggenberg E, Pichler BJ, Virgolini I, Decristoforo C, Haubner R. Knetsch PA, et al. Among authors: virgolini i. Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1303-12. doi: 10.1007/s00259-011-1778-0. Epub 2011 Apr 13. Eur J Nucl Med Mol Imaging. 2011. PMID: 21487838

4

A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.

Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, Shulkin BL, Url C, Widmann G, Prommegger R, Sprinzl GM, Fraedrich G, Virgolini IJ. Kroiss A, et al. Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1800-8. doi: 10.1007/s00259-013-2548-y. Epub 2013 Sep 27. Eur J Nucl Med Mol Imaging. 2013. PMID: 24072345

5

(68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT.

Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, Url C, Gautsch K, Madleitner R, Nilica B, Sprinzl GM, Gastl G, Fraedrich G, Virgolini IJ. Kroiss A, et al. Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):33-41. doi: 10.1007/s00259-014-2892-6. Epub 2014 Aug 19. Eur J Nucl Med Mol Imaging. 2015. PMID: 25134670

6

11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.

Ceci F, Castellucci P, Graziani T, Schiavina R, Chondrogiannis S, Bonfiglioli R, Costa S, Virgolini IJ, Rubello D, Fanti S, Colletti PM. Ceci F, et al. Clin Nucl Med. 2015 May;40(5):e265-70. doi: 10.1097/RLU.0000000000000783. Clin Nucl Med. 2015. PMID: 25783519

7

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, Virgolini IJ. Ceci F, et al. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1284-94. doi: 10.1007/s00259-015-3078-6. Epub 2015 May 15. Eur J Nucl Med Mol Imaging. 2015. PMID: 25975367

8

Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.

Traub-Weidinger T, Putzer D, von Guggenberg E, Dobrozemsky G, Nilica B, Kendler D, Bale R, Virgolini IJ. Traub-Weidinger T, et al. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1995-2001. doi: 10.1007/s00259-015-3114-6. Epub 2015 Jul 15. Eur J Nucl Med Mol Imaging. 2015. PMID: 26173620

9

The ⁶⁸Ga/¹⁷⁷Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV_max values and absorbed dose estimates.

Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, Decristoforo C, Uprimny C, Lukas P, Horninger W, Virgolini I. Scarpa L, et al. Among authors: virgolini i. Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800. doi: 10.1007/s00259-016-3609-9. Epub 2017 Jan 12. Eur J Nucl Med Mol Imaging. 2017. PMID: 28083690 Clinical Trial.

10

Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions.

Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny C, Hofman MS, Eiber M, Schwarzenbock S, Castellucci P, Bellisario C, Chauvie S, Bergesio F, Emmett L, Haberkorn U, Virgolini I, Schwaiger M, Hicks RJ, Krause BJ, Chiti A. Fanti S, et al. Among authors: virgolini i. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1622-1635. doi: 10.1007/s00259-017-3725-1. Epub 2017 May 23. Eur J Nucl Med Mol Imaging. 2017. PMID: 28536833

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

312 results

Search Page